Oculis (NASDAQ:OCS) Reaches New 52-Week High – Time to Buy?

Oculis Holding AG (NASDAQ:OCS) shares reached a new 52-week high on Wednesday . The company traded as high as $28.01 and last traded at $27.69, with a volume of 303370 shares trading hands. The stock had previously closed at $26.90.

Analyst Upgrades and Downgrades

OCS has been the topic of several analyst reports. Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Bank of America decreased their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Oculis in a report on Tuesday, November 11th. Finally, Lifesci Capital assumed coverage on shares of Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oculis has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Trading Down 0.5%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The company’s 50 day simple moving average is $21.74 and its two-hundred day simple moving average is $19.64. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -11.21 and a beta of 0.31.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. Research analysts expect that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc lifted its stake in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares during the last quarter. Syquant Capital Sas bought a new position in Oculis in the 4th quarter worth $3,849,000. Woodline Partners LP lifted its position in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the last quarter. Marshall Wace LLP bought a new stake in Oculis during the second quarter valued at about $393,000. Finally, Bosun Asset Management LLC acquired a new stake in shares of Oculis in the second quarter valued at about $378,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.